Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation
RBGPF
-1.7840
Berliner Boersenzeitung - Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation
EUR
-
AED 3.959931
AFN 74.942278
ALL 101.524416
AMD 433.755616
ANG 1.944394
AOA 896.629001
ARS 392.049845
AUD 1.643361
AWG 1.940983
AZN 1.847013
BAM 1.957387
BBD 2.178416
BDT 118.676197
BGN 1.954522
BHD 0.40656
BIF 3076.458568
BMD 1.078324
BND 1.447107
BOB 7.455078
BRL 5.286057
BSD 1.07888
BTN 89.895352
BWP 14.739084
BYN 3.554514
BYR 21135.151747
BZD 2.174683
CAD 1.464581
CDF 2884.51646
CHF 0.943059
CLF 0.034046
CLP 939.431134
CNY 7.705272
COP 4310.611248
CRC 569.364156
CUC 1.078324
CUP 28.575588
CVE 110.582103
CZK 24.296754
DJF 191.639446
DKK 7.456504
DOP 61.410806
DZD 145.220075
EGP 33.372079
ERN 16.174861
ETB 60.089616
FJD 2.412965
FKP 0.856695
GBP 0.857056
GEL 2.889741
GGP 0.856695
GHS 12.950947
GIP 0.856695
GMD 72.625303
GNF 9278.978972
GTQ 8.447926
GYD 225.719243
HKD 8.423916
HNL 26.688021
HRK 7.593094
HTG 142.717007
HUF 379.721059
IDR 16745.617961
ILS 3.98768
IMP 0.856695
INR 89.857769
IQD 1412.60453
IRR 45572.665952
ISK 150.200322
JEP 0.856695
JMD 167.52968
JOD 0.764965
JPY 158.742229
KES 165.360695
KGS 96.315951
KHR 4442.694975
KMF 492.25664
KPW 970.409136
KRW 1417.764296
KWD 0.332793
KYD 0.899137
KZT 497.354677
LAK 22353.658067
LBP 16212.602168
LKR 352.695888
LRD 202.88616
LSL 20.434904
LTL 3.18401
LVL 0.652267
LYD 5.197314
MAD 10.888374
MDL 19.11794
MGA 4924.706148
MKD 61.65998
MMK 2265.657509
MNT 3723.443077
MOP 8.677775
MRO 384.961507
MUR 47.557015
MVR 16.551774
MWK 1809.967557
MXN 18.632255
MYR 5.034719
MZN 68.203943
NAD 20.434279
NGN 866.430784
NIO 39.62895
NOK 11.81345
NPR 143.832923
NZD 1.75253
OMR 0.415151
PAB 1.078985
PEN 4.052876
PGK 4.019132
PHP 59.721907
PKR 306.462035
PLN 4.326624
PYG 7963.639803
QAR 3.92564
RON 4.967732
RSD 117.09072
RUB 100.065323
RWF 1348.444248
SAR 4.044571
SBD 9.131256
SCR 15.376738
SDG 648.073182
SEK 11.272643
SGD 1.445779
SHP 1.312051
SLE 24.472198
SLL 21296.899999
SOS 616.265707
SRD 40.850121
STD 22319.131095
SYP 14019.420871
SZL 20.433789
THB 37.983423
TJS 11.797572
TMT 3.774134
TND 3.374612
TOP 2.549428
TRY 31.182222
TTD 7.318967
TWD 33.954803
TZS 2695.809951
UAH 39.588357
UGX 4072.39542
USD 1.078324
UYU 42.214218
UZS 13301.127193
VEF 3825610.805758
VES 38.294932
VND 26192.49163
VUV 128.967846
WST 2.939216
XAF 656.50437
XAG 0.045032
XAU 0.000531
XCD 2.914224
XDR 0.811141
XOF 655.089492
XPF 119.693965
YER 269.931462
ZAR 20.413591
ZMK 9706.203717
ZMW 25.947153
ZWL 347.21991
- Israel-Hamas battles rage in south Gaza city
- Hip-hop mogul Sean 'Diddy' Combs again accused of rape
- Supermicro Extends AI and GPU Rack Scale Solutions with Support for AMD Instinct MI300 Series Accelerators
- Venezuela, Guyana open 'communication channels' as border tension mounts
- Rashford dropped by Man Utd for Chelsea clash
- Big US banks balk at new capital rules in Senate hearing
- 'This cannot wait': Biden urges Congress to pass Ukraine aid
- 'Are you not entertained?' Taylor Swift named Time Person of the Year
- LONGi Expands Environmental Protection Efforts with Program to Make Panda Conservation Carbon Neutral
- Golf ball changes will bring back skills, says McIlroy
Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation
LONDON, Nov. 16, 2023 /PRNewswire/ -- The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have approved Kanna Health's Investigational New Drug (IND) application and Clinical Trial Application (CTA), respectively, to start participant enrollment in a Phase 1 first-in-human clinical trial investigating the Safety and Pharmacokinetics of KH-001 Besylate (KH-001) in Healthy Male Subjects.
KH-001 is a unique, proprietary on-demand drug being developed as the first FDA-approved treatment for premature ejaculation. These regulatory approvals signify a potential breakthrough in the management of a widespread condition, impacting up to 20% of men and their partners worldwide.
The Phase 1 study will be conducted in the UK by Simbec-Orion, an experienced full-service Contract Research Organization (CRO).
Dr Ryan Protzko, Kanna Health's President, stated: "Our clinical trial approval on both sides of the Atlantic represents a critical milestone as we officially become a clinical stage company. The study marks the start of a journey towards understanding the therapeutic potential of KH-001 in humans, in cooperation with regulatory bodies in our priority markets."
"This approval allows Kanna Health to advance our understanding of how KH-001 may provide patients with a potentially transformative therapy, where no drug treatments are approved in the US and few treatment options exist worldwide", said Dr Hans-Juergen Gruss, Kanna Health's Chief Medical Officer.
About Premature Ejaculation
Premature ejaculation is the most common form of male sexual dysfunction, impacting ~20% of men (Shindel AW, Althof SE, Carrier S et al.: Disorders of Ejaculation: An AUA/SMSNA Guideline. J Urol 2022), with its most severe form characterized by ejaculation within 1 minute of penetration (~3% of men). Premature ejaculation is associated with secondary psychological effects, with 65% of patients reporting personal distress as a result including anxiety, depression, low self-esteem, and a negative impact on relationships.
About Kanna Health Ltd
Kanna Health is a clinical-stage biopharmaceutical company developing novel fast-acting small molecule therapeutics for sexual and mental health conditions.
Further information:
For further information, please contact John Boghossian (email: [email protected]).
(Y.Berger--BBZ)
